Myricetin, with an IC50 of 690 nM, is also able to inhibit in vitro the activity of human flap endonuclease 1 (hFEN1) protein that is highly expressed in colon cancer cells and is associated with poor prognosis. Here, FEN1 is linked to colonic neoplasm.